Kornimate/medical-research-clean huggingface dataset:
growth hormone treatment in children with hypophosphatemic rickets

Conditions: X Linked Hypophosphatemic Rickets

Summary: this study evaluates the effect on height of a two year treatment with growth hormone in 19 children with x linked hypophosphatemic rickets.


Eligibility criteria:
inclusion criteria: * clinical, biochemical and genetic diagnosis of xlh * height sds \< 2 * at least two years of treatment with oral phosphate and calcitriol exclusion criteria: * uncontrolled rickets (alp\>600 iu) * growth hormone deficiency * hyperparathyroidism, nephrocalcinosis, renal insufficiency * associated disease * previous treatment with growth hormone

Keywords: growth hormone
adding metformin to insulin in controlling pregestational and gestational diabetes mellitus

Conditions: Gestational Diabetes Mellitus in Pregnancy

Summary: the purpose of the study to prove benefits of adding metformin to insulin for controlling presentational and gestational diabetes mellitus and improving neonatal outcome.

the current study was conducted at ain shams university maternity hospital during the period between june 2016 to december 2016. all patients were subjected to: 1. history taking: 2. general and abdominal examination: with particular emphasis on : * body mass index * blood pressure. * fundal height . * estimated fetal weight . 3. insulin and metformin doses : insulin dose: 0.7 iu/kg (at the second trimester of pregnancy). 0.8 iu/kg (at the third trimester of pregnancy). insulin dose was raised at a rate of 1 iu for every 10 mg/dl higher than the target blood glucose concentration. metformin dose : oral metformin at a dose of 1500 mg divided into three doses, were taken with meals, in addition to insulin. if the target blood glucose concentrations were not attained, the dose of metformin was raised to 2000 mg per day. 4. investigations: fasting and two hours postprandial blood glucose levels were measured in two groups of pregnant women: 1. group i: pregnant women who received oral metformin in addition to insulin therapy. 2. group ii: pregnant women who received insulin therapy only.

Eligibility criteria:
inclusion criteria: 1. age 20 - 35 years. 2. gestational age: 20- 36 weeks gestation. 3. singleton pregnancy. 4. women with pregestational or gestational diabetes mellitus exclusion criteria: 1. pregnant women with secondary diabetes (e.g. those on chronic steroid therapy). 2. hypertensive patients. 3. women with impaired liver or renal function 4. non-compliant patients.
minimally invasive simultaneous colorectal and liver surgery

Conditions: Colorectal Cancer

Summary: up to 25% of newly diagnosed patients with colorectal cancer (crc) have liver metastases (lm). simultaneous colorectal and hepatic resection has been proven to be a safe and effective approach in dealing with metastatic colorectal cancer. the aim of this paper is to analyse perioperative and oncological outcomes of minimally invasive (laparoscopic and robotic) one-stage simultaneous resection of liver metastases and colorectal tumor in selected patients affected by colorectal cancer and synchronous liver metastases.

from october 2012 to march 2018 a minimally invasive one-stage resection was offered to selected patients referred to the investigator's institution with a diagnosis of crc and synchronous lm, irrespective of the size and location of the primary and metastatic disease. when feasible, a fully-robotic colorectal and liver resection was performed. prior consent was obtained and full treatment options where submitted to all patients treated. data collected were prospectively analyzed. diagnosis and pre-operative staging were achieved with pancolonoscopy with biopsies and, where contraindicated or not feasible, with ct colonography. pelvic mri with rectal cancer protocol was used for local staging of rectal cancer and total-body contrast-enhanced computed tomography (ct) and liver contrast-enhanced magnetic resonance imaging (mri) for investigation of metastases. in selected cases a ceus (contrast-enhanced ultrasound) or liver biopsy was performed in order to achieve a diagnostic definition. all cases were discussed at multidisciplinary team meeting. criteria for neoadjuvant chemotherapy were liver unresectability with a potential incomplete liver resection with anticipated positive surgical margins and an insufficient liver remnant. absolute contraindications for minimally invasive simultaneous surgery were considered unfitness for surgery due to comorbidities not allowing long operative time, the number of lesions in parenchymal sparing surgery (generally \>5), the pre-operative prediction of vascular resection. relative contraindications were considered the need for major hepatectomy and the finding of new intraoperative lesions, with consequent potential longer operative time. demographic, histopathological, surgical morbidity/mortality and short term peri-operative clinical outcome in all patients undergone simultaneous colorectal and liver resections were prospectively evaluated. morbidity evaluation included all intra-operative and early post-operative (within 30 days) complications and rated according to clavien-dindo classification. all data are expressed as mean values ± range when appropriate

Eligibility criteria:
inclusion criteria: * colorectal primary tumor with synchronous liver metastases * eligibility for minimally-invasive surgery exclusion criteria: * unfitness for prolonged operative time * liver lesions \>5 * pre-operative prediction of vascular resection

Keywords: robotic laparoscopy liver surgery colorectal and synchronous liver metastases simultaneous surgery
patient satisfaction and long-term safety of intravesical aminoglycoside instillations in uti prevention

Conditions: Urinary Tract Infections; Recurrent Urinary Tract Infection

Summary: antimicrobial prophylactic treatment of recurrent uti is limited by emerging resistance, antibiotic allergies and intolerances. intravesical aminoglycoside instillations (iai) have been shown to reduce recurrence rate, without a short-term decline in kidney function or hearing. thus far, treatment satisfaction has not yet been assessed, while this may play an important role in treatment adherence and persistence. moreover, there is no data on the long-term safety of iai, e.g. regarding the development of (pre)malignant bladder lesions.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * currently receiving or having received (no minimal duration) continuous or post-coital iai (gentamicin, tobramycin or amikacin) for recurrent uti prophylaxis and treatment exclusion criteria: * exclusively receiving iai for 'on-demand' treatment of uti and not prophylactic purposes * receiving iai as suppressive therapy for chronic prostatitis * presence of a chronic indwelling catheter * patient has objected to the use of his/her data * inability to provide informed consent

Keywords: intravesical treatment
is chronic abdominal pain in pediatric patients due to small intestinal bacterial overgrowth?

Conditions: Chronic Abdominal Pain; Small Intestinal Bacterial Overgrowth

Summary: chronic abdominal pain (cap) is an extremely pervasive childhood condition and, like ibs in adults, it is one of the functional bowel disorders without a clear framework of understanding or an effective treatment. however, new research suggests that small intestinal bacterial overgrowth (sibo) may be the unifying pathophysiology that explains the variety of symptoms experienced by patients with ibs. as cap in children is believed to be a precursor to ibs in adults, we hypothesize that children with this disorder have a significantly greater prevalence of small intestinal bacterial overgrowth (sibo) than normal, healthy children, and that eradication of bacterial overgrowth with antibiotics will reduce symptoms of chronic abdominal pain in children with this condition. to prove this, we will first aim to determine the prevalence of sibo in both healthy children and those with cap. we will do this by performing a lactulose breath hydrogen test, the gold standard for the noninvasive measurement of sibo, on 40 healthy controls and 80 subjects with cap. we will then assess whether eradication of sibo with antibiotics will reduce symptoms of chronic abdominal pain in children with this condition. to do this we will randomize, in a double-blinded fashion, the 80 cap patients to receive a 10-day course of either the antibiotic rifaximin or a placebo. after completion of the treatment we will evaluate all these patients for eradication of bacterial overgrowth by repeating a lactulose breath hydrogen test. we will also assess for symptom improvement by re-administering questionnaires.


Eligibility criteria:
inclusion criteria: * subjects must be between the ages of 8 and 18 * subjects must be able to swallow pills * healthy controls must be siblings, other family members or friends of the cap subjects or children who are undergoing an overnight fast in order to obtain am labs for another purpose other than this study. * female cap subjects who are sexually active or who may become sexually active during the study will be required to practice an effective method of birth control (e.g., oral contraceptives, contraceptive patch or injection, iud, double barrier method) before entering into the study. * all cap subjects must meet the rome ii criteria for functional bowel disorders associated with abdominal pain or discomfort in children exclusion criteria: subjects will be excluded if they: * have a history of inflammatory bowel diseases, diabetes, cirrhosis or other liver disease, juvenile rheumatoid arthritis, systemic lupus, a history of bowel resection (including gastric, small bowel or colon; gallbladder surgery or appendectomy are not exclusion criteria). * have been treated with antibiotics or probiotics within the past 2 months. * have a history of tb infection or positive mantoux test performed at screening * have a history of allergy to rifampin or rifaximin
high-dose steroid for knee arthroplasty

Conditions: Postoperative Pain; Postoperative Nausea and Vomiting; Knee Osteoarthritis; Perioperative/Postoperative Complications; Surgery

Summary: the purpose of the study is to test a higher dose of steroids(dexamethasone) given just prior to surgery in the setting of fast-track kneesurgery with arthroplasty and the effect on postoperative pain and postoperative inflammation.

this study compares a new high-dose dosage of steroids in the treatment of postoperative pain after knee arthroplasty in a fast-track setting. the investigators compare the already used dose(medium dose) with a new high dose(hd) steroid given as an intravenous bolus after the spinal anaesthesia has been given, but before the surgery starts. the hypothesis is that by attenuating the inflammatory response to the surgery itself by the steroid dexamethasone, the investigators expect a reduction in postoperative pain upon ambulation 24 hours after unilateral knee arthroplasty. patients referred to unilateral total kneearthroplasty because of knee-osteoarthritis on hvidovre hospital, capital region of denmark or vejle hospital, south region of denmark are screened and offered inclusion in the study. the two groups will be randomized and doubleblinded. one group will be treated, as the current guideline in the investigator's orthopedic fast-track arthroplasty center, with the medium dose of steroid (0,3 mg dexamethasone/kg bodyweight). the other group wil be treated with a high dose of steroid (1,0 mg dexamethasone/kg bodyweight). the patients will be monitored the first 7 days after surgery, during the admission to the hospital, and by a pain-diary in the patients own home. blood tests will be taken preoperatively and postoperatively to determine the effect of the highdose steroid on the inflammatory response. also a series of blood tests determining the glucose-metabolism after the steroid-admission.

Eligibility criteria:
inclusion criteria: * age between 40 and 90. * booked for unilateral knee-arthroplasty. * is able to take part in the investigation(selfreported pain and nausea/vomiting) * understands danish or english, or has a translator available. * signed written consent. exclusion criteria: * insulin-dependent diabetes melitus. * ongoing treatment with systemic glucocorticoids or immunosuppressing treatment(apart from inhaled glucocorticoids). * pregnancy/breastfeeding * allergies for the investigational drug. * daily use of opioids. * a pain catastrophizing scale(pcs) score of \>20. * a history of schizophrenia or bipolar diseases, or patients with permanent use of antipsychotic medication.

Keywords: knee arthroplasty knee replacement perioperative medicine
clinical evaluation, biomarkers and metabolomics of sarcopenia in frail older adults at ambulatory clinics

Conditions: Frailty; Sarcopenia

Summary: sarcopenia related mobility dysfunction was a preventable presentation in transitional variation of frailty. however, the definition, associated risk factors, clinical course and outcome of sarcopenia in taiwanese older adults are still under-clarified and need for further study.


Eligibility criteria:
inclusion criteria: * functional decline in recent one year * cognitive impairment * depressive symptom * mobility impairment * fall in recent one year * eating or feeding problems * weight loss * co-morbid conditions≧5 * tracking by different physician ≧3 in recent half year * poly-pharmacy≧8 in recent 3 months * hospitalization ≧1 in recent one year * emergency visits≧2 in recent one year * aged ≧ 80. exclusion criteria: * non-ambulatory (bed-ridden) patients * long-term residents at nursing homes * patients with a life expectancy shorter than six months * impairment in vision, hearing, or communicative ability, making convenience of clinical evaluation during the study period impossible.
precision diagnosis directing hdaci and tki target therapy for adult ph-like all

Conditions: Leukemia; Leukemia, Acute; Leukemia, Lymphoblastic; Leukemia, B-cell

Summary: ph-like all is a recently recognized high-risk subgroup and the optimal therapeutic approaches are poorly characterized. based on the pediatric-inspired, peg-l-asparaginase-intensified and mrd-directed pdt-all-2016 protocol, this open-label, two-arm, multi-site trial pdt-ph-like-all is aimed to evaluate the safety and effect of oral histone deacetylase inhibitor chidamide and dasatinib for adult ph-like all.

ph-like, or bcr-abl1-like lymphoblastic leukemia is neoplasm of lymphoblasts committed to the b-cell lineage that lack the bcr-abl1 translocation but show a pattern of the expression very similar to that seen in bcr-abl1-positive all. chidamide is a novel oral hdaci with promising activity in non-hodgkin lymphoma (nhl). based on the pediatric-inspired, peg-l-asparaginase-intensified and mrd-directed pdt-all-2016 protocol, this open-label, two-arm, multi-site trial is aimed to evaluate the safety and effect of oral histone deacetylase inhibitor (hdaci) chidamide and tyrosine kinase inhibitor (tki) dasatinib for adult ph-like all/lbl. hdaci chidamide and tki dasatinib will be added to chidamide and dasatinib group, respectively, from induction therapy to consolidation therapy (total courses of chidamide treatment: 5 courses for allo-hsct after consolidation module-3; 12 courses for patients non-allo-hsct after consolidation module 1-9). primary study endpoint is event-free survival and secondary study endpoints are complete remission and mrd after induction, adverse event and overall survival. pretreatment: dexamethasone, -3 to 0d; chidamide for chidamide arm: 10mg/d, po qd. dasatinib for dasatinib arm: 100mg/d, po qd. induction:vcr: 1, 8, 15, 22; ida: 1, 8; ctx: 1g/m2, 1; peg-asp: 2000-2500iu/m2, 1, 15; pred: 1-24; mrd assessment: d14, 24, 45, and pre-allo-hsct. vlcam (mrd1/d14\>1%): ctx, d25; arac 50mg/m2, d25-31, 26; 6-mp: 25-31, peg-asp: 26; consolidation module: cm1: arac 2g/m2, q12h, 1-2, dex: 10mg/m2, 1-2, peg-asp: 2, 6-mp: 1-7. it: d1; cm2: mtx 3g/m2, 1, dex: 10mg/m2, 1-2, peg-asp: 2; 6-mp: 1-7; it: d1; cm3: ctx 0.5g/m2, 1-3, peg-asp: 2, 6-mp: 1-7, it: d1. allo-hsct: after cm3 when donors available. non-hsct: finish cm 4-9 and pomp maintenance. cm4-6: repeat cm1-3. re-induction: after cm6. cm7-9: repeat cm1-3. maintenance: pomp-pred: x12m; vcr x12m; mtx: x24m; 6-mpx24m.

Eligibility criteria:
inclusion criteria: * 14-55 years old; * ph-like all newly diagnosed; * signed written informed consent exclusion criteria: * pregnant women; * history of pancreatitis; * history of diabetes; * history of active peptic ulcer disease in the past 6 months; * history of arteriovenous thrombosis in the past 6 months; * severe active infection; * allergic to any drugs in pdt-ph-like-all.

Keywords: acute lymphoblastic leukemia ph-like tyrosine kinase inhibitor histone deacetylase inhibitor
health professions students and faculty perceptions of poisoning severity

Conditions: Poisoning

Summary: inaccurate perceptions of the severity of an exposure may result in unnecessary visits to the emergency department or health care facility which can result in crowding of emergency departments, unnecessary utilization of valuable health care resources, unnecessary treatments, and or mistakes / errors resulting in harm to the patient. inaccurate perceptions about the severity of an exposure can result in delays in proper evaluation and treatment resulting in harm or in some cases death of the patient.

consumers and health professionals are often surprised about the toxicity (or lack of toxicity) after exposure to a number of pharmaceutical or non-pharmaceutical agents. past experience with the survey used in this study has indicated that consumers and health professional perform about the same. most individuals answer less than 50% of questions incorrectly. pharmacy students will be asked to participate in a short (5-7 minutes) survey (see below) that contains 21-short cases involving an exposure to a pharmaceutical or non-pharmaceutical agent. all cases involve children less than 19 years of age. participants will be asked to indicate their year in pharmacy school (1st or 2nd) and their gender (f/m). the survey will be given after a scheduled examination or other classroom activity and will not involve class time. students will be provided a link to an online version of the survey. conclusions will be derived through the analysis of the data. at a later date, all students in the class (whether they participated in the survey or not)students will be provided a link to video that describes the correct answers to each of the cases and an explanation.

Eligibility criteria:
inclusion criteria: * all pharmacy students who agree to participate exclusion criteria: * none
hemopatch versus no hemopatch (renal transplant)

Conditions: Renal Failure

Summary: kidney transplantation remains one of the most common organ transplanted today but the surgical technique has changed very little from the original pelvic operation. the deceased donor renal transplant poses a particular challenge to the surgeon due to lack of detailed pre operative vascular assessment. the hemopatch is a promising new sealing synthetic hemostatic agent with a novel dual mechanism of action that is more convenient to apply rather then using other hemostatic agents, which require warming and/or mixing.


Eligibility criteria:
inclusion criteria: * patients at least 18 years of age and capable of giving informed consent * patients scheduled for deceased donor renal transplant surgery exclusion criteria: * patient undergoing live related transplant surgery. * patient having uncorrectable bleeding diathesis. * any patient in the no hemopatch group requiring additional haemostatic agents for achieving hemostasis like fibrillar or surgical.
brain and genetic predictors of individual differences in pain and analgesia

Conditions: Pain, Acute

Summary: the purpose of the study is to gain a better understanding of pain processing in the brain. our understanding of how pain is processed in the brain is limited. we are testing for individual differences in pain perception and emotion.


Eligibility criteria:
inclusion criteria: * participants must be registered in the colorado community twin sample (cts). exclusion criteria: * not being registered in the colorado community twin sample (cts). * any mri contraindications.
pilot project on external vestibular prosthesis in chronic subjective dizziness

Conditions: Dizziness Chronic

Summary: researchers are gathering information on the safety and effectiveness of a new device called the balancebelt.

ten consecutive subjects, ages 25-70 years, diagnosed with chronic subjective dizziness (cds) and ten healthy age and gender matched subjects will be asked to perform tests involving walking and balance while wearing the balancebelt. the balancebelt is a lightweight belt that will be worn under the clothes around the subjects waist and uses sensitive motion detectors and vibrates against the skin at four locations to provide information about posture and motion.

Eligibility criteria:
subject population: 20 patients with diagnosis of chronic subjective dizziness (csd) and 10 normal volunteers. inclusion criteria: * subjects will be 25-70 years of age inclusive and pregnant women may participate. * patients will have csd as their primary diagnosis for the cause of their balance and dizziness complaints provided by the behavioral medicine program for dizziness, a division of the department of psychiatry \& psychology. * normal volunteers will have a negative history of otologic \& neurologic disorders and no history of dizziness and balance problems. * normal volunteers will have normal findings on a screening office examination for peripheral and central vestibular system involvement (see methods for details of the examination) and screening for normal or symmetrical hearing loss of explainable origin. exclusion criteria: * patients with positive indications from testing of peripheral and/or central vestibular system involvement that is felt to be influencing the symptoms reported beyond the csd alone. * patients with mobility restriction that would prevent participating in the tests or the intensive therapy trials. * subjects with hearing impairment that interferes with oral communication.

Keywords: pilot study assessment of sway phase therapy trial phase